Drug name - Daliresp

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9468598 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient Feb, 2023

(4 months from now)

US8431154 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient Feb, 2023

(4 months from now)

US8536206 ASTRAZENECA Process for the preparation of roflumilast Mar, 2024

(1 year, 5 months from now)

US8604064 ASTRAZENECA Process for the preparation of roflumilast Mar, 2024

(1 year, 5 months from now)

US8618142 ASTRAZENECA Process for the preparation of roflumilast Mar, 2024

(1 year, 5 months from now)

Drugs and Companies using ROFLUMILAST ingredient

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
250MCG TABLET;ORAL Prescription
500MCG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.